» Articles » PMID: 39001529

Real-World Clinical Utility of Targeted RNA Sequencing in Leukemia Diagnosis and Management

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Jul 13
PMID 39001529
Authors
Affiliations
Soon will be listed here.
Abstract

Gene fusions are key drivers in acute leukemia, impacting diagnosis and treatment decisions. We analyzed 264 leukemia patients using targeted RNA sequencing with conventional karyotyping and reverse transcription polymerase chain reaction (RT-PCR). Leukemic fusions were detected in 127 patients (48.1%). The new guidelines introduced additional diagnostic criteria, expanding the spectrum of gene fusions. We discovered three novel fusions (, , and ). We analyzed recurrent breakpoints for the and rearrangements. Targeted RNA sequencing showed consistent results with RT-PCR in all tested samples. However, when compared to conventional karyotyping, we observed an 83.3% concordance rate, with 29 cases found only in targeted RNA sequencing, 7 cases with discordant results, and 5 cases found only in conventional karyotyping. For the five cases where known leukemic gene rearrangements were suspected only in conventional karyotyping, we conducted additional messenger RNA sequencing in four cases and proved no pathogenic gene rearrangements. Targeted RNA sequencing proved advantageous for the rapid and accurate interpretation of gene rearrangements. The concurrent use of multiple methods was essential for a comprehensive evaluation. Comprehensive molecular analysis enhances our understanding of leukemia's genetic basis, aiding diagnosis and classification. Advanced molecular techniques improve clinical decision-making, offering potential benefits.

References
1.
Chen X, Wang W, Yeh J, Wu Y, Oehler V, Naresh K . Clinical Validation of FusionPlex RNA Sequencing and Its Utility in the Diagnosis and Classification of Hematologic Neoplasms. J Mol Diagn. 2023; 25(12):932-944. DOI: 10.1016/j.jmoldx.2023.09.007. View

2.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

3.
Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

4.
Annala M, Parker B, Zhang W, Nykter M . Fusion genes and their discovery using high throughput sequencing. Cancer Lett. 2013; 340(2):192-200. PMC: 3675181. DOI: 10.1016/j.canlet.2013.01.011. View

5.
Kim B, Lee H, Shin S, Lee S, Choi J . Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies. J Mol Diagn. 2018; 21(1):163-170. DOI: 10.1016/j.jmoldx.2018.09.002. View